KR102419683B1 - Asthma relief or therapeutic biologic composition - Google Patents
Asthma relief or therapeutic biologic composition Download PDFInfo
- Publication number
- KR102419683B1 KR102419683B1 KR1020200069432A KR20200069432A KR102419683B1 KR 102419683 B1 KR102419683 B1 KR 102419683B1 KR 1020200069432 A KR1020200069432 A KR 1020200069432A KR 20200069432 A KR20200069432 A KR 20200069432A KR 102419683 B1 KR102419683 B1 KR 102419683B1
- Authority
- KR
- South Korea
- Prior art keywords
- honey
- asthma
- weight
- licorice
- astragalus
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims description 10
- 230000001225 therapeutic effect Effects 0.000 title 1
- 235000012907 honey Nutrition 0.000 claims abstract description 37
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 21
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 21
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 21
- 229940010454 licorice Drugs 0.000 claims abstract description 21
- 241001061264 Astragalus Species 0.000 claims abstract description 19
- 235000006533 astragalus Nutrition 0.000 claims abstract description 19
- 210000004233 talus Anatomy 0.000 claims abstract description 19
- 241000063156 Squatina squatina Species 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 241000202807 Glycyrrhiza Species 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 18
- 240000002045 Guettarda speciosa Species 0.000 claims description 12
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 12
- 240000007594 Oryza sativa Species 0.000 claims description 12
- 235000007164 Oryza sativa Nutrition 0.000 claims description 12
- 235000009566 rice Nutrition 0.000 claims description 12
- 241000411851 herbal medicine Species 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229940109850 royal jelly Drugs 0.000 claims description 4
- 235000013871 bee wax Nutrition 0.000 claims description 3
- 239000012166 beeswax Substances 0.000 claims description 3
- 235000015110 jellies Nutrition 0.000 claims description 3
- 239000008274 jelly Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 abstract description 7
- 238000002347 injection Methods 0.000 abstract description 7
- 235000007516 Chrysanthemum Nutrition 0.000 abstract description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 description 10
- 238000001467 acupuncture Methods 0.000 description 9
- 210000003979 eosinophil Anatomy 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 241000045403 Astragalus propinquus Species 0.000 description 4
- 241000257303 Hymenoptera Species 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 229940092253 ovalbumin Drugs 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 229960004784 allergens Drugs 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 229940124748 beta 2 agonist Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- DYXBSXBXZNSAPO-UHFFFAOYSA-M 1,1-dimethylpyrrolidin-1-ium;iodide Chemical compound [I-].C[N+]1(C)CCCC1 DYXBSXBXZNSAPO-UHFFFAOYSA-M 0.000 description 1
- 241000332371 Abutilon x hybridum Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001487769 Adenophora remotiflora Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 240000001810 Angelica gigas Species 0.000 description 1
- 235000018865 Angelica gigas Nutrition 0.000 description 1
- 241001105098 Angelica keiskei Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010058530 Peripheral nerve palsy Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 241001441724 Tetraodontidae Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- UIERETOOQGIECD-ARJAWSKDSA-N angelic acid group Chemical group C(\C(\C)=C/C)(=O)O UIERETOOQGIECD-ARJAWSKDSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 238000009341 apiculture Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960001012 codeine hydrochloride Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- -1 detoxifying Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000350 mc(t) Anatomy 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 천식을 해소하는 천연복합물을 개시한다.
본 발명에 따르는 천식을 해소하는 천연복합물에 의하면, 모싯대, 감초, 황기, 당귀, 토종꿀을 포함하는 것을 특징으로 하는데, 이에 의할 때 종래에 한방 침술에 적용하여 약침의 약침액 성분으로 사용하거나, 주사로 직접 주사를 하던 것과는 달리 용이하게 경구 복용하여 천식 완화, 획기적인 치료가 가능한 천식을 해소하는 효과가 있다.The present invention discloses a natural complex for relieving asthma.
According to the natural complex for relieving asthma according to the present invention, it is characterized in that it contains chrysanthemum, licorice, astragalus, angelfish, and native honey. , Unlike direct injection, it is easy to take orally to relieve asthma and to relieve asthma that can be treated innovatively.
Description
본 발명은 천식을 해소하는 천연복합물에 관한 것으로, 종래에 한방 침술에 적용하여 약침의 약침액 성분으로 사용하거나, 주사로 직접 주사를 하던 것과는 달리 용이하게 경구 복용하여 천식 완화, 획기적인 치료가 가능한 천식을 해소하는 천연복합물에 관한 것이다.The present invention relates to a natural complex for relieving asthma, which can be used as a medicinal acupuncture component of traditional herbal acupuncture by applying it to traditional oriental acupuncture, or can be easily taken orally to relieve asthma and treat epoch-making asthma, unlike direct injection. It relates to a natural complex that relieves the
천식은 만성 알레르기성 호홉기 질환으로, 폐 속에 있는 기관지가 아주 예민해진 상태를 말하는데, 예를 들어 기관지가 좁아져서 숨쉬기 어렵운 경우나 빈번하고 약한 숨소리를 내며 기침하는 증상 등을 발현하는 병증을 말하며, 이러한 기관지의 알레르기 염증 반응 때문에 발생하는 알레르기성 질환이다. Asthma is a chronic allergic respiratory disease, which refers to a condition in which the bronchi in the lungs are very sensitive. , is an allergic disease caused by an allergic inflammatory reaction of these bronchial tubes.
이런 증상들이 반복적 발작적으로 발현되어 기관지의 염증으로 기관지 점막이 부어 오르고 기관지 근육이 경련을 일으키면서 기관지가 막혀감으로써 숨이 벅차오르게 되어 환자 본인의 고통을 수반한다.These symptoms appear repeatedly, causing the bronchial mucosa to swell due to inflammation of the bronchial tubes, and the bronchial muscles spasm and block the bronchial tubes.
이러한 알레르기성 질환은 유전적 요인과 환경적 요인이 상호 작용하여 발병하며, 대개의 경우 완치가 쉽지 않은 대표적인 난치성 만성 질환이며, 천식을 유발하는 요인으로는 원인 물질과 악화 요인이 있고, 원인 물질을 알레르겐(allergen)이라고 하는데, 대표적인 알레르겐으로는 집먼지 진드기, 꽃가루, 동물 털이나 비듬, 바퀴벌레, 식품, 약물 등이 있으며, 대표적인 악화 요인으로는 감기, 담배연기 실내오염, 대기오염, 식품첨가제, 운동 등 신체적 활동, 기후 변화, 황사, 스트레스 등이 있다.These allergic diseases are caused by the interaction of genetic factors and environmental factors, and in most cases, are a representative intractable chronic disease that is not easy to cure. It is called an allergen, and typical allergens include house dust mites, pollen, animal hair or dander, cockroaches, food, and drugs. These include physical activity, climate change, yellow dust, and stress.
또한, 천식은 기도의 만성 염증성 질환으로 기도 염증과 기도 과민증은 기침, 천명(喘鳴), 호홉 곤란, 가슴 답답함 등의 증상을 일으키며, 알레르기 질환의 특징적인 염증 양상을 보이는데, 알레르겐을 감지하면 활성화된 점막 비만세포는 히스타민(기관지 수축과 염증반응), 류코트리엔(leukptrienes), 프로스타글란딘D2(기관지 수축제)와 같은 기도수축 매개체를 분비하고, 활성화된 호산구와 자연살해 T세포(TCR invariant natural killer T cell)가 증가하며, 기도상피세포에 손상을 주는 사이토카인(염증반응을 전반적으로 조절)과 케모카인(염증세포 동원) 등의 염증물질을 분비하여 증상이 유발된다. In addition, asthma is a chronic inflammatory disease of the airways, and airway inflammation and airway hypersensitivity cause symptoms such as cough, wheezing, shortness of breath, and chest tightness. Mucosal mast cells secrete airway constriction mediators such as histamine (bronchial constriction and inflammatory response), leukptrienes, and prostaglandin D2 (bronchoconstrictor), and activate eosinophils and TCR invariant natural killer T cells. Symptoms are caused by secretion of inflammatory substances such as cytokines (regulating the overall inflammatory response) and chemokines (mobilizing inflammatory cells) that damage airway epithelial cells.
아울러, 평활근 세포의 비후(hypertrophy)와 과형성(hyperplasia)이 발생하는 것과 함께 VEGF(vascular endothelial growth factor)와 같은 성장인자의 영향으로 기도 내 혈관이 증식되며 기도 벽의 두께가 증가한다.In addition, along with the occurrence of hypertrophy and hyperplasia of smooth muscle cells, the blood vessels in the airway proliferate under the influence of growth factors such as vascular endothelial growth factor (VEGF), and the thickness of the airway wall increases.
한편, 천식은 만성적이고 재발이 많은 질환으로, 치료 방법으로는 증상을 완화시키고 재발을 방지하기 위한 약제를 사용하는 약물요법과, 천식의 원인 물질을 찾아 원인 알레르겐 노출을 최소화하고 악화인자로부터 회피하는 회피요법이 있으며, 원인 물질을 소량씩 주사하여 알레르기 체질을 개선하는 면역요법 등의 치료방법들이 있다.On the other hand, asthma is a chronic and recurrent disease, and treatment methods include drug therapy using drugs to relieve symptoms and prevent recurrence, and to find substances that cause asthma to minimize exposure to causative allergens and avoid exacerbating factors. There is avoidance therapy, and there are treatment methods such as immunotherapy, which improves allergic constitution by injecting a small amount of a causative agent.
그 중 약물요법에 사용하는 천식 치료 약물은 좁아진 기관지를 짧은 시간 내에 완화시키는 증상 완화제와 기관지의 알레르기 염증을 억제하여 천식발작을 예방하는 질병 조절제로 구분한다. 대표적인 증상 완화제로 베타2항진제(작용제), 테오필린(theophylline)으로 대표되는 잔틴(xanthine)계 약물, 부교감신경 차단제(anticholinergics; 항콜린제) 등이 널리 사용되고 있으며, 질병 조절제로는 부신피질스테로이드와 류코트리엔 조절제 등이 사용되고 있으나, 베타2 항진제와 같은 증상 완화제는 근본적인 천식을 근본적으로 치료하지 못하기 때문에 규칙적으로 사용해야 하며 이로 인한 신체 부작용을 유발할 수 있다. Among them, asthma treatment drugs used in drug therapy are divided into symptom relievers that relieve narrowed bronchi within a short time and disease control agents that prevent asthma attacks by suppressing allergic inflammation of the bronchi. As representative symptom relievers, beta-2 agonists (agonists), xanthine drugs such as theophylline, and anticholinergics (anticholinergics) are widely used. However, symptom relievers such as beta-2 agonists do not fundamentally treat asthma, so they must be used regularly and may cause side effects in the body.
스테로이드 또한 오랫동안 사용하는 경우 혈당 상승, 혈압 상승, 체중 증가, 기분 변화, 골다공증, 위궤양 등과 같은 심각한 부작용이 생길 수 있으며, 아울러 전체 천식 환자 중에서 약 5% 정도가 약에 대한 내성이 생가서 약물이 천식에 전혀 반응하지 않아 상당히 위험한 상태에 빠지는 문제가 있다.If steroids are also used for a long time, serious side effects such as blood sugar rise, blood pressure rise, weight gain, mood changes, osteoporosis, gastric ulcer, etc. There is a problem in that it does not respond at all to a very dangerous state.
따라서, 본 발명이 해결하고자 하는 기술적 과제는 종래에 한방 침술에 적용하여 약침의 약침액 성분으로 사용하거나, 주사로 직접 주사를 하던 것과는 달리 용이하게 경구 복용하여 천식 완화, 획기적인 치료가 가능한 천식을 해소하는 천연복합물을 제공하는 것이다.Therefore, the technical problem to be solved by the present invention is to solve asthma, which can be used as a medicinal acupuncture component of acupuncture or directly by injection by applying it to traditional oriental acupuncture, or by taking it orally, which can be easily treated orally to relieve asthma and achieve breakthrough treatment to provide a natural complex that
본 발명은 상술한 기술적 과제를 해결하기 위하여, 모싯대, 감초, 황기, 당귀, 토종꿀을 포함하는 것을 특징으로 하는 천식을 해소하는 천연복합물을 제공한다.The present invention provides a natural complex for relieving asthma, characterized in that it contains rice seed, licorice, Astragalus, Angelica, native honey in order to solve the above-described technical problem.
본 발명의 다른 실시예에 의하면, 상기 모싯대는 그 뿌리을 포함하는 것일 수 있다.According to another embodiment of the present invention, the seedling may include its roots.
본 발명의 다른 실시예에 의하면, 상기 모싯대 100 중량부에 대하여 감초 8 내지 12 중량부, 황기 8 내지 12 중량부, 당귀 10 내지 16 중량부, 토종꿀 100 내지 200 중량부를 사용하는 것일 수 있다.According to another embodiment of the present invention, it may be to use 8 to 12 parts by weight of licorice, 8 to 12 parts by weight of astragalus, 10 to 16 parts by weight of angelicae, 100 to 200 parts by weight of native honey with respect to 100 parts by weight of the rice seedlings.
본 발명의 다른 실시예에 의하면, 상기 모싯대, 감초, 황기, 당귀의 추출물인 진액과 토종꿀을 혼합한 것일 수 있다.According to another embodiment of the present invention, it may be a mixture of the extracts of the rice seedlings, licorice, astragalus, and Korean angelfish and native honey.
본 발명의 다른 실시예에 의하면, 상기 토종꿀은 꿀 이외에 로열젤리, 화분, 밀랍을 더 포함하는 것일 수 있다.According to another embodiment of the present invention, the native honey may further include royal jelly, pollen, and beeswax in addition to honey.
본 발명의 다른 실시예에 의하면, 상기 진액과 토종꿀의 혼합은 혼합물의 점도가 4000 내지 8000cP에 이르도록 수행되는 것일 수 있다.According to another embodiment of the present invention, the mixing of the extract and native honey may be performed so that the viscosity of the mixture reaches 4000 to 8000 cP.
본 발명의 다른 실시예에 의하면, 상기 모싯대, 감초, 황기, 당귀, 토종꿀은 모싯대, 감초, 황기, 당귀를 건조시킨 후에 분쇄하여 토종꿀과 함께 혼합하여 환 형태로 제조된 것일 수 있다.According to another embodiment of the present invention, the rice seedlings, licorice, Astragalus, Angelica, and native honey may be prepared in the form of a ring by drying and then grinding and mixing with native honey.
본 발명의 다른 실시예에 의하면, 상기 모싯대, 감초, 황기, 당귀에서 유효성분의 진액을 추출하여 토종꿀과 혼합한 상태인 젤리 형태로 제조된 것일 수 있다.According to another embodiment of the present invention, it may be prepared in the form of a jelly in a state in which the extract of the active ingredient is extracted from the rice seedlings, licorice, Astragalus, and Angelica, and mixed with native honey.
본 발명에 따르는 천식을 해소하는 천연복합물에 의하면, 종래에 한방 침술에 적용하여 약침의 약침액 성분으로 사용하거나, 주사로 직접 주사를 하던 것과는 달리 용이하게 경구 복용하여 천식 완화, 획기적인 치료가 가능한 천식을 해소하는 효과가 있다.According to the natural complex for relieving asthma according to the present invention, it is possible to relieve asthma and treat epoch-making asthma by easily taking it orally, unlike conventionally applied to oriental acupuncture and used as a medicinal acupuncture component of acupuncture, or directly injected by injection. has the effect of resolving
이하 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 명세서는 다수의 특정한 구현물의 세부사항들을 포함하지만, 이들은 어떠한 발명이나 청구 가능한 것의 범위에 대해서도 제한적인 것으로서 이해되어서는 안되며, 오히려 특정한 발명의 특정한 실시형태에 특유할 수 있는 특징들에 대한 설명으로서 이해되어야 한다. 개별적인 실시형태의 문맥에서 본 명세서에 기술된 특정한 특징들은 단일 실시형태에서 조합하여 구현될 수도 있다. While this specification contains numerous specific implementation details, they should not be construed as limitations on the scope of any invention or claim, but rather as descriptions of features that may be specific to particular embodiments of particular inventions. should be understood Certain features that are described herein in the context of separate embodiments may be implemented in combination in a single embodiment.
한편, 본 명세서와 도면에 개시된 본 발명의 실시 예들은 이해를 돕기 위해 특정 예를 제시한 것에 지나지 않으며, 본 발명의 범위를 한정하고자 하는 것은 아니다. 여기에 개시된 실시 예들 이외에도 본 발명의 기술적 사상에 바탕을 둔 다른 변형 예들이 실시 가능하다는 것은, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 자명한 것이다.On the other hand, the embodiments of the present invention disclosed in the present specification and drawings are merely presented as specific examples to aid understanding, and are not intended to limit the scope of the present invention. It will be apparent to those of ordinary skill in the art to which the present invention pertains that other modifications based on the technical spirit of the present invention can be implemented in addition to the embodiments disclosed herein.
본 발명에 따르는 천식을 해소하는 천연복합물은 모싯대, 감초, 황기, 당귀, 토종꿀을 포함하는 것을 특징으로 한다.The natural complex for relieving asthma according to the present invention is characterized in that it contains rice seedlings, licorice, astragalus, Angelica, and native honey.
상기 모싯대는 초롱꽃과에 속하는 다년생 초본식물로서, 고려시대의 이두향명으로는 장의피(獐矣皮)·저의화차(猪矣和次)라 하였고, 조선시대에는 계노지(季奴只)라 하였으며, 『동의보감(東醫寶鑑)』·『훈몽자회(訓蒙字會)』·『촌가구급방(村家救急方)』 등에는 ‘계로기’로 기록되어 있으며, 학명은 Adenophora remotiflora (S. et Z.) MIQ.인데, 뿌리가 도라지를 닮았다고 해서 토길경으로 불리기도 한다.As a perennial herbaceous plant belonging to the chrysanthemum family, it was called Jangpi (獐矣皮) and Jeouihwacha (猪矣和次) as the name of Iduhyang in the Goryeo Dynasty, and Gyenoji (季奴只) in the Joseon Dynasty. , 『Donguibogam』, 『Hunmongjahoe (訓蒙字会)』, 『Chongagugeukbang』, etc. are recorded as 'Gyerogi', and the scientific name is Adenophora remotiflora (S. et Z). .) It is MIQ., but it is also called Togilgyeong because the root resembles a bellflower.
이러한 토길경은 숲속의 약간 그늘진 곳에서 자라는 식물로 높이 40∼100㎝이고 뿌리가 굵고, 잎은 난상 심장형으로 어긋나 있으며, 길이 5∼20㎝, 너비 3∼8㎝로서 끝이 뾰족하고 가장자리에 예리한 톱니가 있고, 꽃은 자주색으로 8∼9월에 핀다.This plant grows in a slightly shady place in the forest. It is 40-100 cm high, has thick roots, and has alternate heart-shaped leaves, 5-20 cm long and 3-8 cm wide, with sharp tips and sharp edges. It has sawtooth, and the flowers are purple and bloom from August to September.
특히, 토길경의 뿌리에는 해열·해독·거담 작용이 있어서 감기로 열이 심하고 기침이 날 때 이용되며, 가래를 삭히기도 한다. 산후 임산부의 이뇨를 촉진시키고 약물의 중독도 풀어주는 효과가 있다.In particular, the root of Togilgyeong has antipyretic, detoxifying, and expectorant properties, so it is used when coughing and fever with a cold, and it is also used to clear phlegm. It promotes diuresis in pregnant women after childbirth and has the effect of relieving drug addiction.
상기 감초(Glycyrrhiza uralensis FISCH)는 뿌리를 건조시켜서 한약재로 사용하는데, 그 맛이 달기 때문에 감초라 하고, 감미가 있는 글리시리진과 글라브릭산, 슈크로즈, 글루코즈, 리퀴리틴, 리코리시딘 등을 함유하고 있으며, 특히, 글리시리진은 디프테리아 독소, 파상풍 독소, 염산 코데인, 초산 스트리키닌, 뱀독·복어독 등을 해독하는 작용을 하며, 항염증 작용이 있어 부종을 억제하고, 혈액 중의 콜레스테롤치를 내려주어 혈압강하의 효과가 있으며, 담즙의 분비를 촉진시키고 진해작용 및 진통작용을 하기도 한다.The licorice (Glycyrrhiza uralensis FISCH) is used as a herbal medicine by drying the root, and it is called licorice because its taste is sweet. In particular, glycyrrhizin detoxifies diphtheria toxin, tetanus toxin, codeine hydrochloride, strychnine acetate, snake venom, pufferfish venom, etc. It has a depressant effect, and promotes the secretion of bile, and also acts as an antitussive and analgesic.
아울러, 황기(黃耆, Astragalus propinquus 또는 Mongolian milkvetch)는 한국·중국·일본에 분포하는 여러해살이풀로 산지의 바위틈에 자라며, 높이 40-70cm이며 전체에 흰색의 부드러운 잔털이 있고, 줄기는 총생하며 잎은 6-11쌍의 소엽으로 이루어진 기수 1회우상복엽이며, 소엽은 길이 약 1-2cm로 난상타원형이며 잎가장자리는 밋밋하고, 턱잎은 피침형으로써 끝이 길게 뾰족하고, 엽액에서 총상으로 대가 긴 꽃이삭이 나오며 5-10개의 꽃이 달리며, 7-8월에 황백색 꽃이 피며 길이 약 2cm이고 작은 꽃자루는 길이 약 3mm이고, 꽃받침은 길이 약 5mm이고 흑갈색 털이 있으며 5개로 갈라지며, 수술은 10개이고 꼬투리는 긴 타원형으로 양 끝이 뾰족하고 길이 2-3cm이며 5-7개의 종자가 들어 있다.In addition, Astragalus propinquus or Mongolian milkvetch (黃耆, Astragalus propinquus, or Mongolian milkvetch) is a perennial plant distributed in Korea, China, and Japan that grows in crevices of rocks in mountainous areas, is 40-70 cm high, has white soft fine hairs, and has a stalk. The leaf is a radix one-time right-sided bifoliate composed of 6-11 pairs of leaflets. The leaflet is about 1-2cm long and ovate oval, the leaf edge is flat, the stipule is lanceolate with a long pointed tip, and the cost is from the leaf axil to the raceme. Long spikelets come out, 5-10 flowers hang, yellow-white flowers bloom in July-August, about 2cm long, small peduncle about 3mm long, calyx about 5mm long, blackish brown hairs, split into 5, stamens There are 10, and the pods are long oval, pointed at both ends, 2-3cm long, and contain 5-7 seeds.
흔히 약초로서 재배하며 한방에서는 가을에 채취하여 노두(蘆頭)와 잔뿌리를 제거하고 햇빛에 말린 것을 한약재의 황기라 하며, 강장·지한(止汗)·이뇨 등의 효능이 있어 신체허약·피로권태·기혈허탈·자궁탈·내장하수·식은땀·말초신경마비·반신불수·부종·만성신장염 등에 처방하기도 한다.It is commonly cultivated as a medicinal herb, and in oriental medicine, collected in autumn, removing the outcrops and fine roots, and dried in sunlight is called astragalus of herbal medicine. It is also prescribed for qi-hyeol collapse, uterine dislocation, visceral drainage, cold sweat, peripheral nerve palsy, hemiplegia, edema, and chronic nephritis.
또 한편, 상기 당귀(angelica gigas root)는 깊은 산속에서 자생하나 주로 재배되며, 줄기는 높이가 1~2m 정도이고 뿌리를 약물로 사용하는데 뿌리는 비후하며 유즙을 함유하고 향기가 강하고, 뿌리는 길이가 20~25㎝ 정도이고, 지름이 1~5㎝ 정도가 되며, 주성분은 정유, 자궁흥분성 성분, 자당, 비타민 E 등이 있고, 성질은 온하며 독이 없고, 신맛과 단맛이 나는데 약간 쓴맛이 돌며, 주로 심장·간·비장의 3경에 들어가 작용하는 성질이 강하다고 알려져 있다.On the other hand, the angelica gigas root grows wild in deep mountains, but is mainly cultivated, the stem is about 1 to 2 m in height, and the root is used as a drug. is about 20 to 25 cm, and the diameter is about 1 to 5 cm, and the main ingredients are essential oil, uterine excitatory ingredients, sucrose, vitamin E, etc. , is known to have a strong property of entering and acting mainly in the heart, liver, and spleen.
또한, 생리통에도 효과가 있으며, 백작약·연호삭·향부자 등을 배합하여 사용하고, 이외에 무월경, 생리불순에도 효과가 있으며, 동계·건망·불면·정신불안 등의 심혈허 증상에는 당귀로 보혈하고 진정시키고, 비혈허로 인해 몸이 마르고 초췌해 보일 때에는 당귀로 양혈건비하기도 한다.In addition, it is effective for menstrual cramps, and it is used in combination with Earl Potion, Yeonhosak, and Hyangbuja. In addition, it is also effective for amenorrhea and menstrual irregularities. When the body looks dry and exhausted due to non-hyeol-heo, it is sometimes used as an angelic yanghyeol-geonbi.
아울러, 어지럽고 눈이 아물거리고 귀에서 소리가 나고 근육경련이 있을 때도 당귀를 써서 양혈·양간하고, 또한 어혈에 사용하는데 타박, 염좌 등의 외상이나 혈관질환으로 인해 생긴 내출혈, 혈류정체, 종장, 통증에 대해서 혈액순환을 개선·진통시켜 치료 하는 것으로 알려져 있다.In addition, Angelica is used for yang and yangyang when dizzy, closed eyes, ringing in the ears, and muscle cramps, and is also used for eohyeol. It is known to improve blood circulation and relieve pain.
한편, 상기 토종꿀은 토봉으로 채취할 수 있는데, 토봉은 이동하지 않고 한곳에서만 벌을 키우는 방식으로, 이 때문에 대부분의 토종꿀은 꽃꿀의 종류가 있는 양봉꿀과 달리 소위 ‘잡꿀’이며, 토종벌이 들과 산을 자유롭게 날아다니며 다양한 꽃에서 꿀을 채취하기 때문이다. On the other hand, the native nectar can be collected by using a soil-bong, and the soil-bong does not move and grows bees only in one place. This is because it flies freely in the fields and mountains, collecting nectar from various flowers.
또한 토종꿀의 또 다른 특징은 1년에 단 한 차례, 늦가을 서리가 내린 뒤 수확하는데, 토종꿀은 벌집 안에서 오랜 기간 숙성되면서 수분이 거의 빠져나가 꿀이 진하고, 꿀 속에 로열젤리와 화분(花粉)·밀랍 등이 섞여 있는 것도 양봉꿀과 다른 점이다.Another characteristic of native honey is that it is harvested only once a year, after frost in late autumn. As native honey matures for a long time in the beehive, almost no moisture is lost, so the honey is thick, and royal jelly and pollen are added to the honey. It is different from beekeeping honey in that it contains beeswax.
이러한 꿀은 꽃 속에 함축되어 있는 소량의 꿀을 벌의 꿀샘에 담아 효소작용으로 저장된 것이며, 상기 로열젤리는 벌이 분비하는 물질로 여왕벌 애벌레의 주식량이고, 화분은 꽃의 수술에서 발의 다리와 몸에 묻혀 꿀과 함께 벌의 효소작용을 거쳐 저장되어 필수아미노산, 고단위 천연비타민, 지방, 탄수화물, 미네랄등을 포함하고 있으며, 밀랍은 벌의 체내에 밀납샘으로부터 뽑아내어 벌집을 짓거라 꿀을 저장하는데 사용되는 것이다.This nectar is stored by enzymatic action by storing a small amount of nectar contained in flowers in the honey glands of bees, and the royal jelly is a substance secreted by bees and is the main amount of the queen bee larvae, and pollen is used for the legs and body of the feet in the stamens of flowers. It is buried and stored through the enzymatic action of bees with honey, and contains essential amino acids, high-unit natural vitamins, fats, carbohydrates, and minerals. will be used
또 한편, 상술한 모싯대, 감초, 황기, 당귀, 토종꿀는 함량이 중요한데, 모싯대 100 중량부에 대하여 감초 8 내지 12 중량부, 황기 8 내지 12 중량부, 당귀 10 내지 16 중량부, 토종꿀 100 내지 200 중량부를 사용할 수 있다.On the other hand, the above-mentioned mother seed, licorice, Astragalus, Angelica, and native honey content is important, based on 100 parts by weight of the rice seedling, licorice in 8 to 12 parts by weight, Astragalus 8 to 12 parts by weight, Angelica 10 to 16 parts by weight, native honey 100 to 200 parts by weight may be used.
상술한 모싯대, 감초, 황기, 당귀, 토종꿀은 모싯대, 감초, 황기, 당귀를 건조시킨 후에 분쇄하여 토종꿀과 함께 혼합하여 환 형태로 만들어 복용할 수 있다.The above-mentioned rice seed, licorice, Astragalus, Angelica, and native honey can be taken in the form of pills by drying and then grinding and mixing with native honey.
또한, 상기 모싯대, 감초, 황기, 당귀에서 유효성분의 진액을 추출하여 토종꿀과 혼합한 상태인 젤리 형태로 만들어 복용할 수 있다.In addition, the extract of the active ingredient from the seedlings, licorice, astragalus, and angelfish can be made and taken in the form of a jelly mixed with native honey.
먼저 모싯대, 감초, 황기, 당귀를 건조시킨 상태나 건조시킨 상태에서 분쇄된 상태의 생약재들을 에탄올 수용액에 침지하여 중탕으로 생약재에서 유효성분을 추출하게 된다.First, the herbal medicines in a dried or dried state, licorice, astragalus, and Angelica keiskei are immersed in an aqueous ethanol solution to extract active ingredients from the herbal medicines in a hot water bath.
여기서 중탕으로 진액을 추출하여도 에탄올로 인하여 화재의 우려가 있으므로, 에탄올의 농도는 5 내지 15 중량%가 바람직한데, 만일 15 중량%를 초과하면 화재의 우려는 물론 충분한 유효성분 이전에 에탄올이 증발할 수 있으며 반대로 5 중량 % 미만이면, 유효성분 추출이 어려워 에탄올 수용액을 수시로 보충해야 하는 번거러움이 있을 수 있다.Here, even when extracting the essence with a bath, there is a risk of fire due to ethanol, so the concentration of ethanol is preferably 5 to 15% by weight. Conversely, if it is less than 5% by weight, it may be difficult to extract the active ingredient, so there may be inconvenience of frequently replenishing the aqueous ethanol solution.
다음으로, 중탕개시후 에탄올 수용액이 초기 투입량에 대하여 10 내지 60 %가 남은 상태에서 중탕을 종료하여 생약재들로부터 추출된 진액을 수득할 수 있다.Next, after starting the bath, 10 to 60% of the ethanol aqueous solution remains with respect to the initial input amount, and the bath is terminated to obtain the extract extracted from the herbal medicines.
만일 중탕개시후 에탄올 수용액이 초기 투입량에 대하여 10 % 미만이 되면 생약재의 섬유성분들에 진액이 늘러붙을 수 있으며, 반대로 60 %를 초과하면 충분히 진액 추출이 진해되기 어려울 수 있다.If the ethanol aqueous solution is less than 10% of the initial input amount after the start of the bath, the extract may stick to the fiber components of the herbal medicine. Conversely, if it exceeds 60%, it may be difficult to sufficiently extract the extract.
진액을 수득한 이후에 생약재들을 가압하여 진액을 추가적으로 추출할 수 있음은 물론이다.Of course, it is possible to additionally extract the extract by pressing the herbal medicines after obtaining the extract.
다음으로 토종꿀과 균일하게 혼합하게 되는데, 진액에서 침전물이 발생하지 않도록 진액에 토종꿀을 침지하여 흔들어 주거나 회전시켜 혼합하며, 토종꿀에는 수분이 거의 없어 균일한 혼합이 어려운 관계상 혼합시 진액의 온도를 80 ℃ 내지 100℃를 유지하는 것이 중요하다.Next, it is uniformly mixed with native honey. To prevent sediment from occurring in the essence, the native honey is immersed in the essence and shaken or rotated to mix. It is important to maintain the temperature between 80 °C and 100 °C.
만일 혼합시 진액의 온도를 80 ℃ 미만으로 하면, 진액에서 에탄올 수용액의 증발이 어려워 알콜성분이 과량 잔존할 수 있고, 반대로 100 ℃를 초과하면 진액에서 에탄올 수용액이 빨리 증발하여 토종꿀과의 균일한 혼합이 어려울 수 있다.If the temperature of the extract is less than 80 ℃ during mixing, it is difficult to evaporate the aqueous ethanol solution from the extract, so an excess of alcohol may remain. Mixing can be difficult.
한편, 상기 진액과 토종꿀의 혼합물의 점도가 4000 내지 8000cP에 이르면 교반을 종료하고 자연냉각시키는데, 만일 4000 cP 미만이면 환이나 젤리 형태로 사용이 어렵고 용매성분이 많이 잔존할 수 있으며 반대로 8000cP를 초과하면 균일한 혼합이 어려울 수 있다. On the other hand, when the viscosity of the mixture of the extract and native honey reaches 4000 to 8000 cP, the stirring is terminated and natural cooling is performed. It may be difficult to achieve uniform mixing.
실시예 및 비교예Examples and Comparative Examples
실시예 1로는 모싯대 1600 g, 감초 150 g, 황기 150 g, 당귀 200 g를 건조시킨 후 곱게 분쇄하여 토종꿀 2.2 kg과 혼합하여 직경 0.5 내지 2㎜의 환을 준비하였고, 실시예 2로는 모싯대 1600 g, 감초 150 g, 황기 150 g, 당귀 200 g를 건조시킨 후 곱게 분쇄하여 에탄올 수용액(에탄올 10 중량%)에 침지하여 중탕으로 80℃르 유지한 후, 에탄올 수용액의 양이 초기 투입량 대비 50 %가 남은 상태에서 중탕을 종료하여 여과를 거쳐 진액을 수득하였고, 90 ℃를 유지하며 토종꿀과 함께 교반하여 꿀과 혼합물의 점성이 6000 cP에 이르러 교반을 종료하고 젤리형태의 천연복합물을 준비하였다.In Example 1, 1600 g of rice seedlings, 150 g of licorice, 150 g of astragalus, and 200 g of Angelica were dried and finely ground and mixed with 2.2 kg of native honey to prepare a ring with a diameter of 0.5 to 2 mm. g, 150 g of licorice, 150 g of Astragalus, 200 g of Angelica basil, pulverized and immersed in an aqueous ethanol solution (10% by weight of ethanol) and maintained at 80 ° C. In the remaining state, the bath was terminated to obtain the essence through filtration, and the mixture was stirred with local honey while maintaining 90 ° C. When the viscosity of the honey and mixture reached 6000 cP, stirring was terminated, and a jelly-like natural complex was prepared.
비교예로는 건지황 100 중량부, 향부자 100 중량부, 작약 100 중량부, 생강 100 중량부, 당귀 100 중량부, 홍화 75 중량부, 감초 75 중량부를 증류수 및 62.5 중량% 농도의 에탄올 수용액을 1 : 0.25 부피비로 혼합한 혼합용매를 준비하고, 다음으로, 상기 생약 복합물 1kg 당 상기 혼합용매 3.25L 를 혼합하여 혼합용액을 제조하였으며, 다음으로, 상기 혼합용액을 교반 및 80~82℃로 가열하고 증류시켜서 농축된 추출액을 수득하였으며, 이를 멸균 생리식염수(N/S)(Lot No: 12062, 공급원: JW Pharmaceutical)와 혼합 및 35 부피% 농도로 희석하여 주사제를 제조하였다.As a comparative example, 100 parts by weight of dried turmeric, 100 parts by weight of hyangbuja, 100 parts by weight of peony, 100 parts by weight of ginger, 100 parts by weight of angelicae, 75 parts by weight of safflower, 75 parts by weight of licorice, distilled water and an aqueous solution of ethanol with a concentration of 62.5% by weight 1: Prepare a mixed solvent mixed in a 0.25 volume ratio, and then, 3.25L of the mixed solvent per 1 kg of the herbal compound was mixed to prepare a mixed solution, and then, the mixed solution was stirred and heated to 80 ~ 82 ℃ and distilled to obtain a concentrated extract, which was mixed with sterile physiological saline (N/S) (Lot No: 12062, source: JW Pharmaceutical) and diluted to a concentration of 35% by volume to prepare an injection.
실험예 1Experimental Example 1
BALB/c 마우스에서 오브알부민(ovalbumin)으로 천식(asthma)을 유발하고 투여하여 폐 기관지 세척액(bronchoalveolar lavage fluid, BALF) 중 총 백혈구 수(WBC), 호산구(Eosinophil) 및 세포감별계수(differential cell count, IgE)를 측정하였다.Asthma induced and administered with ovalbumin in BALB/c mice. Total white blood cell count (WBC), eosinophil and differential cell count in bronchoalveolar lavage fluid (BALF). , IgE) was measured.
여기서 실험에 이용된 쥐는 천식시험에 널리 사용되고 있는 것으로 주령이 입수시 6주, 본 실험시 7 주된 암컷이며, 입수 후 6일간 시험을 실시하는 동물실 내에서 순화시키고, 매일1회 이상 관찰하였고, 순화기간에는 적색 유성 매직으로, 투여 및 관찰기간에는 흑색 유성 매직을 이용한 표식법을 사용하여 식별하였으며, 사육상자에는 개체식별카드를 부착하였고, 상기 마우스는 온도 23 ± 3℃, 상대습도 55 ± 15%, 환기횟수 10 - 20회/hr, 조명시간 12 시간 및 조도 150 ~ 300 Lux로 유지되는 사육구역에서 사육하였으며, 적량의 깔개를 담은 폴리카보네이트 사육상자에서 순화, 투여기간에 4마리 이하를 사육상자로 사육하였고, 순화기간 중 건강한 것으로 판정한 동물의 체중을 측정하여 순위화하고, 각 군의 평균체중이 균일하게 분포하도록 하였다.The rats used in this experiment are widely used for asthma tests. They are females at 6 weeks of age at the time of acquisition and 7 weeks of age at the time of this experiment. Red oil magic was used during the acclimatization period and black oil magic was used during administration and observation period, and an individual identification card was attached to the breeding box. %, ventilation frequency 10 - 20 times/hr, lighting time 12 hours, and illuminance of 150 ~ 300 Lux were bred in a breeding area. The animals were bred in boxes, and the weights of animals determined to be healthy during the acclimatization period were measured and ranked, and the average weight of each group was uniformly distributed.
천식 유발물질로는 냉장 보관된 오브알부민(OVA)(Catalog 번호: A5503, 공급원: Sigma Aldrich, Louis, MO, USA)을 사용하였으며, 면역 보조물질로 냉장 보관된 알루미늄 하이드록사이드(Aluminum hydroxide, Alum)(Catalog 번호: 77161, 공급원: Thermo Fisher Scientific lnc, Waltham, MA, USA,)를 사용하였다. As an asthma trigger, refrigerated ovalbumin (OVA) (Catalog number: A5503, source: Sigma Aldrich, Louis, MO, USA) was used, and refrigerated aluminum hydroxide (Alum) was used as an immune adjuvant. ) (Catalog number: 77161, source: Thermo Fisher Scientific lnc, Waltham, MA, USA,) was used.
그리고, 양성 대조물질로 실온 보관된 덱사메타손(Dexamethasone, DEX)(제조번호: 13099, 공급원: SAMNAM Pharm, 충남, 대한민국)을 사용하였다.And, as a positive control material, dexamethasone (DEX) stored at room temperature (Product Number: 13099, Source: SAMNAM Pharm, Chungnam, Korea) was used.
마우스의 천식 유발을 위한 복강주사제는 OVA 20 μg+, Alum 1 mg+, 멸균 생리식염수 500 μL/head로 주 2회로 2주간 주사하였다.The intraperitoneal injection for inducing asthma in mice was injected twice a week with OVA 20 μg+, Alum 1 mg+, and sterile physiological saline 500 μL/head for 2 weeks.
그리고, 천식이 유발된 마우스에 대조군은 생리식염수를, 양성군은 덱사메타손을 주사하였고, 비교예 하기 표 1과 같이 주 2회로 4주간 주사하였고, 주사액량과 경구투입량을 표기하였다.In addition, the asthma-induced mice were injected with physiological saline for the control group and dexamethasone for the positive group, and were injected twice a week for 4 weeks as shown in Table 1 below in Comparative Example, and the injection amount and oral dosage were indicated.
또한, 4주 후, 마우스 혈액으로부터 WBC(white blood cell), 호산구(Eosinophil) 및 IgE를 측정하였고, 그 평균값 측정 결과를 하기 표 2에 나타내었다.In addition, after 4 weeks, white blood cells (WBC), eosinophils, and IgE were measured from mouse blood, and the average measurement results are shown in Table 2 below.
표 2를 참고하면, 대조군에 비해 양성군 및 비교예의 경우, WBC, 호산구 및 IgE가 크게 낮아지는 결과를 확인할 수 있으며, 실시예1, 2의 경우, 양성군 보다는 WBC, 호산구 및 IgE 측정 수치가 조금 높지만, 대조군과 비교할 때 WBC, 호산구 및 IgE가 크게 낮아지는 결과를 보였다.Referring to Table 2, in the case of the positive group and the comparative example compared to the control group, it can be seen that WBC, eosinophil and IgE are significantly lowered, and in the case of Examples 1 and 2, WBC, eosinophil and IgE measurement values are higher than that of the positive group Although slightly higher, compared with the control group, WBC, eosinophils and IgE were significantly lowered.
이에 대하여 비교예의 경우에는 대조군에 비해 WBC, 호산구 및 IgE 측정 수치가 낮기는 하지만, 양성군이나 실시예들에 비하여 WBC, 호산구 및 IgE 감소 효과가 감소하는 결과를 나타냈다.In contrast, in the case of the comparative example, although the WBC, eosinophil and IgE measurement values were lower than that of the control group, the WBC, eosinophil and IgE reducing effect was decreased compared to the positive group or Examples.
실험예2Experimental Example 2
천식 환자 20명을 상대로 10명씩 실시예1, 2에 의한 한약조성물들을 복용하게 하여 그 결과를 각각 아래 표 3, 표 4에 나타냈다.(1주에 2회 12주간 복용하였으며, 4주 마다 환자의 천식 완화 여부를 확인함)For 20 asthma patients, 10 each were given the herbal composition according to Examples 1 and 2, and the results are shown in Tables 3 and 4 below, respectively. check for asthma relief)
상기 실험을 통해, 본 발명에 따르는 한약조성물에 의하여 천식을 완화시킬 수 있음을 확인할 수 있었다.Through the above experiment, it was confirmed that asthma can be alleviated by the herbal composition according to the present invention.
Claims (8)
모싯대, 감초, 황기, 당귀를 건조시킨 상태나 건조시킨 상태에서 분쇄된 상태의 생약재들을 에탄올의 농도는 5 내지 15 중량%인 에탄올 수용액에 침지하여 중탕으로 생약재에서 유효성분을 추출하고, 중탕개시후 에탄올 수용액이 초기 투입량에 대하여 10 내지 60 %가 남은 상태에서 중탕을 종료하여 생약재들로부터 추출된 진액을 수득한 후 혼합시 진액의 온도를 80 ℃ 내지 100℃를 유지하며 토종꿀과 균일하게 혼합하여 혼합물의 점도가 4000 내지 8000cP가 되도록 제조된 것을 특징으로 하는 천식을 해소하는 천연복합물.
Contains rice seedlings, licorice, Astragalus, Angelica, and local honey,
After immersing the dried or pulverized herbal medicines in an aqueous solution of ethanol with an ethanol concentration of 5 to 15% by weight, active ingredients are extracted from the herbal medicines in a bath, and after starting the bath After completing the bath with 10 to 60% of the initial amount of ethanol solution remaining, the extract is obtained from herbal medicines, and the temperature of the extract is maintained at 80 ° C to 100 ° C during mixing and uniformly mixed with local honey. A natural complex for relieving asthma, characterized in that it is prepared so that the viscosity of the mixture is 4000 to 8000 cP.
상기 모싯대는 그 뿌리을 포함하는 것을 특징으로 하는 천식을 해소하는 천연복합물.
The method of claim 1,
The mother seed is a natural complex for relieving asthma, characterized in that it contains the root.
상기 모싯대 100 중량부에 대하여 감초 8 내지 12 중량부, 황기 8 내지 12 중량부, 당귀 10 내지 16 중량부, 토종꿀 100 내지 200 중량부를 사용하는 것을 특징으로 하는 천식을 해소하는 천연복합물.
The method of claim 1,
8 to 12 parts by weight of licorice, 8 to 12 parts by weight of astragalus, 10 to 16 parts by weight of angelicae, and 100 to 200 parts by weight of native honey based on 100 parts by weight of the rice seedlings, a natural complex for relieving asthma.
상기 토종꿀은 꿀 이외에 로열젤리, 화분, 밀랍을 더 포함하는 것을 특징으로 하는 천식을 해소하는 천연복합물.
The method of claim 1,
The native honey is a natural complex to relieve asthma, characterized in that it further comprises royal jelly, pollen, and beeswax in addition to honey.
상기 모싯대, 감초, 황기, 당귀, 토종꿀은 모싯대, 감초, 황기, 당귀를 건조시킨 후에 분쇄하여 토종꿀과 함께 혼합하여 환 형태로 제조된 것을 특징으로 하는 천식을 해소하는 천연복합물.
The method of claim 1,
The mother seed, licorice, Astragalus, Angelica, and native honey are dried and then crushed and mixed with native honey to relieve asthma, characterized in that they are prepared in the form of a pill.
상기 모싯대, 감초, 황기, 당귀에서 유효성분의 진액을 추출하여 토종꿀과 혼합한 상태인 젤리 형태로 제조된 것을 특징으로 하는 천식을 해소하는 천연복합물.The method of claim 1,
A natural complex for relieving asthma, characterized in that it is prepared in the form of a jelly mixed with native honey by extracting the extract of the active ingredient from the rice seedlings, licorice, astragalus, and angelfish.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200069432A KR102419683B1 (en) | 2020-06-09 | 2020-06-09 | Asthma relief or therapeutic biologic composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200069432A KR102419683B1 (en) | 2020-06-09 | 2020-06-09 | Asthma relief or therapeutic biologic composition |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210152672A KR20210152672A (en) | 2021-12-16 |
KR102419683B1 true KR102419683B1 (en) | 2022-07-11 |
Family
ID=79033172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200069432A KR102419683B1 (en) | 2020-06-09 | 2020-06-09 | Asthma relief or therapeutic biologic composition |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102419683B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240087884A (en) | 2022-12-12 | 2024-06-20 | 한남대학교 산학협력단 | Health functional asthma improvement and treatment composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101045025B1 (en) * | 2009-12-29 | 2011-06-30 | 조신영 | Pharmaceutical composition for preventing or treatment of asthma |
KR102017799B1 (en) * | 2019-03-22 | 2019-09-03 | 김성기 | The crude drugs composition of decreation or treating bronchial asthma, phamacopuncture injection of oriental medicinie containing the same, Injection containing the same, Acupuncturing method of oriental medicinie using the same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130036800A (en) * | 2011-10-05 | 2013-04-15 | 경희대학교 산학협력단 | A composition for stimulating immune response comprising an extract of angelicae gigantis radix and astragali radix |
-
2020
- 2020-06-09 KR KR1020200069432A patent/KR102419683B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101045025B1 (en) * | 2009-12-29 | 2011-06-30 | 조신영 | Pharmaceutical composition for preventing or treatment of asthma |
KR102017799B1 (en) * | 2019-03-22 | 2019-09-03 | 김성기 | The crude drugs composition of decreation or treating bronchial asthma, phamacopuncture injection of oriental medicinie containing the same, Injection containing the same, Acupuncturing method of oriental medicinie using the same |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240087884A (en) | 2022-12-12 | 2024-06-20 | 한남대학교 산학협력단 | Health functional asthma improvement and treatment composition |
Also Published As
Publication number | Publication date |
---|---|
KR20210152672A (en) | 2021-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011026267A1 (en) | Antiphlogistic, antioncotic and analgesic chinese herbal composition,preparative method and usage thereof | |
US11883458B2 (en) | Herb medicine composition for alleviating or treating asthma, and oriental pharmacopuncture solution containing same and injection containing same | |
KR20110129673A (en) | Herbal composition for removing hangover and beverage containing the same | |
KR101348102B1 (en) | A composition comprising extracts of herbal mixture for treating or preventing interstitial cystitis | |
KR102419683B1 (en) | Asthma relief or therapeutic biologic composition | |
Ravinder et al. | Ethnobotanical studies on karnal district, Haryana, India | |
CN104256166A (en) | Functional feed for treating bovine bluetongue and preparation method thereof | |
KR101901297B1 (en) | a stress reducible and deep sleep inducing oil composition and the producing method | |
Dwivedi et al. | Indian herbal medicines used for treatment of dementia: an overview | |
Reshu et al. | Hidden potential of doob grass-an Indian traditional drug | |
KR20150033797A (en) | Pharmaceutical composition for prevention and treatment of atopic skin disease | |
Mariyam Roqaiya et al. | A review on traditional uses and phytochemical properties of Mimusops elengi Linn. | |
Roy et al. | Herbs Used In Peptic Ulcer: A Review. | |
KR100609643B1 (en) | Herbal medicine composition for the treatment of dermatitis and a method of manufacturing the same | |
KR102165214B1 (en) | a stress reducible and deep sleep inducing oil composition and the good sleeping bed using thereof | |
KR102116816B1 (en) | Cosmetic composition comprising extracts of Taheebo, Dictamnus dasycarpus Turcz., Hemiptelea davidii and Melia azedarach L. for preventing and treating atopic dermatitis | |
CN104288234A (en) | Traditional Chinese medicine preparation for preventing and curing caprinae respiratory system diseases, and production method thereof | |
CN108992538A (en) | A kind of Chinese medicine preparation and preparation method of hair growth | |
KR20160082496A (en) | a Gamikyejakjimo tang composition of functon of athritis protection and treatment | |
CN103735670B (en) | Natural plant lotion for head sore | |
Tunan | Phytochemical investigation of Nymphaea Pubescens and study of its antimicrobial activities | |
CN102406692A (en) | Chinese medicinal composition for treating oral cavity Behcet disease and preparation method thereof | |
CN109568496B (en) | Detection method of traditional Chinese medicine composition for treating diabetes | |
KR20120041841A (en) | Herbal composition for acne treatment and skin enhancement | |
Ayat | YARROW, THE HEALING MILFOIL |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |